About TPM Sciences
TPM Sciences is a biotechnology company developing novel approaches to overcome immunotherapy resistance in solid tumors.
Our Mission
Cancer treatment has an efficacy problem. We’re solving it. Checkpoint inhibitors transformed oncology. But most patients don’t respond. We’re targeting the metabolic barriers that drive this resistance.
The Challenge
Immunotherapy is one of the most important advances in medicine. It works by unleashing the immune system against cancer. But despite billions invested in new combinations, a fundamental problem remains unsolved. 60-70% of patients fail to respond to checkpoint inhibitors due to metabolic barriers in the tumor microenvironment.
Our Approach
Targeting the metabolic-immune interface to overcome resistance.
- The Science: Emerging science points to metabolic dysfunction as a key driver of treatment resistance. We identify specific metabolic pathways that suppress immune function.
- The Solution: TPM Sciences is developing therapies that target these pathways to improve outcomes for patients who fail standard treatment.
- The Focus: We are laser-focused on solid tumors with strong metabolic drivers, where our platform has the highest probability of success.